Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Remdesivir  COVID-19 treatment studies for Remdesivir  C19 studies: Remdesivir  Remdesivir   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
Comparative study between the therapeutic effect of remdesivir versus hydroxychloroquine in COVID-19 hospitalized patients
Eldeen et al., Microbes and Infectious Diseases, doi:10.21608/mid.2021.85877.1177
Eldeen et al., Comparative study between the therapeutic effect of remdesivir versus hydroxychloroquine in COVID-19.., Microbes and Infectious Diseases, doi:10.21608/mid.2021.85877.1177
Aug 2021   Source   PDF  
  All Studies   Meta
Small study comparing 25 HCQ and 25 remdesivir hospitalized patients, reporting faster viral clearance with remdesivir. The article proof is missing the results for the HCQ group. Confounding by time is likely - remdesivir patients were after HCQ patients in time, and treatment protocols improved over the period of the study.
[Gérard, Wu, Zhou] show significantly increased risk of acute kidney injury with remdesivir.
Eldeen et al., 16 Aug 2021, peer-reviewed, 5 authors.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperRemdesivirAll
Abstract: Microbes and Infectious Diseases 2021; 2(4): 642-650 Microbes and Infectious Diseases Journal homepage: Original article Comparative study between the therapeutic effect of remdesivir versus hydroxychloroquine in COVID-19 hospitalized patients Maii A. Shams Eldeen *1, Mohamed S. Abdelghafar 2, Hoda A. Ibrahim 3, Al Shimaa A. Taha 4, Marwa S. Taha 1 1- Department of Medical Microbiology and Immunology, Faculty of Medicine, Tanta University, Egypt. 2- Department of Anesthesia, Surgical Intensive Care and Pain, Faculty of Medicine, Tanta University. Egypt. 3- Department of Medical Biochemistry, Faculty of Medicine, Tanta University. Egypt. 4- Department of Pharmacology, Faculty of Medicine, Tanta University. Egypt. ARTICLE INFO ABSTRACT Article history: Background: Up till now, no evidence based studies have recommended specific therapeutic modality to treat corona virus disease-19 (COVID-19). Many regimens were tested since the outbreak has started. Among commonly tested drugs are hydroxychloroquine, an antimalarial agent, which was proposed based on its anti-inflammatory as well as antiviral effects and remdesivir, an antiviral that showed invivo and invitro activity against the formerly known corona-viruses The Food & Drug Administration (FDA) approved using remdesivir in the treatment of severe cases of COVID-19. Objectives: To evaluate the effectiveness of remdesivir versus hydroxychloroquine against SARS-CoV-2 in terms of infectivity period in hospitalized COVID-19 patients. Methods: Fifty patients that were clinically diagnosed with Covid-19 admitted to Tanta University Isolation Hospital from June - September, 2020 were included in this study and divided into 2 groups. Group I had hydroxychloroquine as the main therapeutic agent in their treatment regimen, while group II had the antiviral remdesivir instead. Laboratory testing involved nasopharyngeal swabbing which was transported immediately to Tanta University Hospital laboratory for Real-time PCR. Results: There was a significant better outcome and shorter infectivity period in group 2 who received the antiviral remdesivir. Conclusions: Remdesivir showed significant better outcome in COVID19 hospitalized patients, as it reduced period needed for clinical improvement while administration of hydroxychloroquine was not associated with better outcome or increased risk to the patients. Received 30 June 2021 Received in revised form 13 August 2021 Accepted 16 August 2021 Keywords: SARS-CoV-2 Remdesivir Hydroxychloroquine Real-time PCR
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop